FEATURED EDITORIAL
A sponsor should approach diversion risk by embedding controls into the three phases of the CDMO relationship: selection, the agreement, and ongoing management.
- You Can't CAPA What You Can't Locate
- Well, What Do You Know? The Government May Be Relenting On WuXi AppTec
- Sustainability In Manufacturing: Power And Digital Twins
- My CDMO Is A Constellation of Unified Skills. Is Yours?
- Developing Your Vapor Phase Hydrogen Peroxide Cycle
- The 2026 Pharma R&D AI Sourcing Map: Partnerships, Concentration, Inflection
- Beyond The Plate Count: How To Build A Defensible Environmental Monitoring Trend Review
GUEST COLUMNISTS
-
Developing Your Vapor Phase Hydrogen Peroxide Cycle
Vapor phase hydrogen peroxide has been used for decades as a surface decontaminant in pharma/biotech, but there has been little guidance on how to establish the parameters. Here's an industry consensus from BioPhorum.
-
The 2026 Pharma R&D AI Sourcing Map: Partnerships, Concentration, Inflection
A Beroe analysis of 2026 pharma AI deals shows discovery still dominates, suppliers are consolidating, and clinical development is the next AI sourcing frontier.
-
Beyond The Plate Count: How To Build A Defensible Environmental Monitoring Trend Review
Determining whether a drug manufacturing environment is stable, drifting, or developing a recurring loss-of-control signal requires integrated trend evaluation.
-
What Europe's Draft Annex 22 Actually Asks Of Human Oversight Of AI
The European Commission and the Pharmaceutical Inspection Co-operation Scheme (PIC/S) consulted on draft Annex 22, Artificial Intelligence. Here's what you should know.
-
How Is Your Glass Supplier Adapting To Europe's Energy Crisis?
Europe's glass manufacturers, including those making pharmaceutical lab glassware, have experienced a series of energy shocks. Many have adopted sustainability practices.
-
The EU Overhauls Pharma Laws: What You Need To Know
On Sept. 18, the Council of the EU published the almost-final text of a major overhaul of the EU pharmaceutical laws. The final binding text is expected to be published very soon.
-
September 2026 — CDMO Opportunities And Threats Report
Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.
-
An Incomplete Response: Will The FDA Finish What It Started With Real-Time CRLs?
FDA’s real-time CRL releases face legal and operational hurdles. Could AI-assisted redaction make transparency faster and more consistent?
PHARMA OUTSOURCING WHITE PAPERS
-
Value Reimagined: Unlocking ROI And Efficiency In Drug Development
Separate CDMO, CRO, and clinical supply contracts may carry a price that a Tufts CSDD valuation tries to measure in oncology, and the answer shifts sharply depending on phase and modality.
-
Commercial Technology Transfer Of Oral Solid Dosage Products
Mastering commercial manufacturing transfers means aligning regulatory requirements with site execution. Learn strategies to manage equipment differences, material risks, and global supply continuity.
-
How Much Can You Learn From Limited Drug Substance?
For peptide programs and other high-value APIs, each vial of drug product is a budget line, and the real question is which studies truly need the active material and which can do without it.
-
Controlling Plasmid Forms For LVV And mRNA Production
Plasmid monomer and multimer forms affect downstream applications differently. Learn how optimized analytics and control strategies support LVV performance and mRNA production quality.
-
Integrating Analytical And Process Development For Cell Therapies
Integrating process development, RNA sequencing, and flow cytometry guides media selection, tracks phenotypic shifts, and accelerates cell therapy commercialization and regulatory progress.
-
Designing, Selecting, And Developing Bioconjugates For Clinical Success
Accelerate the development of complex bioconjugates to unlock new possibilities for targeted therapies and advance the next generation of precision medicine.
PHARMA OUTSOURCING APP NOTES & CASE STUDIES
- Where The Money Goes: Amorphous Dispersion Manufacturing
- From Early Development To Commercial Launch: An End-To-End Partnership
- Unlocking Higher Complex Capsule Yields Through More Efficient Manufacturing
- Selecting The Right Chromatography Strategy
- Optimizing Particle Properties For Difficult Small Molecules
NEWSLETTER ARCHIVE
REPORTING
EDITORIAL COLLECTIONS
Take a closer look at the decisions shaping biopharma outsourcing. Our Editorial Collections examine how organizations select CDMOs, manage external relationships, transfer processes, and weigh the business realities of outsourced development and manufacturing.
More Editorial CollectionsPRODUCTS & SERVICES
ON-DEMAND WEBINARS
- From Clinical Success To Commercial Readiness
- Operation Readiness Strategy To Improve Project Delivery And Startup Success
- Bacterial Retention Testing: Demonstrating Sterilizing Filter Performance
- Decoding Biologics Tech Transfer: Process Performance Across Sites And Scales
- Planning For Scale From The Start: Where Early Development Decisions Create Commercial Risk

